HLA-C and neoplasm: To address tumour immune escape mechanisms beyond MHC downregulation, combining MHC restoration with ICB, such as anti‐PD‐1/PD‐L1, offers a promising strategy to simultaneously enhance antigen presentation and alleviate T cell inhibition, thereby promoting robust antitumour immunity.130, 164